TZLS 501
Alternative Names: Anti-IL6R mAb - Tiziana Life Sciences; NI-1201; TZLS-501Latest Information Update: 28 Jul 2024
At a glance
- Originator Light Chain Bioscience
- Developer Light Chain Bioscience; Tiziana Life Sciences
- Class Anti-inflammatories; Antivirals; Monoclonal antibodies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Inflammation
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in United Kingdom (Parenteral)
- 31 Dec 2023 Tiziana Life Sciences has patent protection for TZLS 501 worldwide, prior to December 2023
- 31 Dec 2023 Tiziana Life Sciences has patents pending for TZLS 501 worldwide, prior to December 2023